The U.S. Court of Appeals for the Federal Circuit Thursday dismissed Momenta Pharmaceuticals Inc.'s appeal of a Patent Trial and Appeal Board (PTAB) decision sustaining patent claims protecting Bristol-Myers Squibb Co.'s (BMS) arthritis drug, Orencia.